85 related articles for article (PubMed ID: 8429302)
1. Expression and immunogenicity of the entire human T cell leukaemia virus type I envelope protein produced in a baculovirus system.
Arp J; Ford CM; Palker TJ; King EE; Dekaban GA
J Gen Virol; 1993 Feb; 74 ( Pt 2)():211-22. PubMed ID: 8429302
[TBL] [Abstract][Full Text] [Related]
2. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
[TBL] [Abstract][Full Text] [Related]
3. Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene.
Ibuki K; Funahashi SI; Yamamoto H; Nakamura M; Igarashi T; Miura T; Ido E; Hayami M; Shida H
J Gen Virol; 1997 Jan; 78 ( Pt 1)():147-52. PubMed ID: 9010298
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the antibody response to three different versions of the HTLV-I envelope protein expressed by recombinant vaccinia viruses: induction of neutralizing antibody.
Ford CM; Arp J; Palker TJ; King EE; Dekaban GA
Virology; 1992 Nov; 191(1):448-53. PubMed ID: 1413516
[TBL] [Abstract][Full Text] [Related]
5. Induction of neutralizing antibodies against HTLV-I envelope proteins after combined genetic and protein immunizations in mice.
Grange MP; Armand MA; Audoly G; Thollot D; Desgranges C
DNA Cell Biol; 1997 Dec; 16(12):1439-48. PubMed ID: 9428792
[TBL] [Abstract][Full Text] [Related]
6. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
[TBL] [Abstract][Full Text] [Related]
7. Expression and immunogenicity in rats of recombinant adenovirus 5 DNA plasmids and vaccinia virus containing the HTLV-I env gene.
Kazanji M; Bomford R; Bessereau JL; Schulz T; de Thé G
Int J Cancer; 1997 Apr; 71(2):300-7. PubMed ID: 9139857
[TBL] [Abstract][Full Text] [Related]
8. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1.
Jacobson S; Reuben JS; Streilein RD; Palker TJ
J Immunol; 1991 Feb; 146(4):1155-62. PubMed ID: 1704032
[TBL] [Abstract][Full Text] [Related]
9. Different B-cell responses to human T-cell lymphotropic virus type I (HTLV-I) envelope synthetic peptides in HTLV-I-infected individuals.
Ida H; Kurata A; Eguchi K; Kawakami A; Migita K; Fukuda T; Nakamura T; Kusumoto Y; Berzofsky JA; Nagataki S
J Clin Immunol; 1991 May; 11(3):143-51. PubMed ID: 1890164
[TBL] [Abstract][Full Text] [Related]
10. Antibodies to the envelope glycoprotein of human T cell leukemia virus type 1 robustly activate cell-mediated cytotoxic responses and directly neutralize viral infectivity at multiple steps of the entry process.
Kuo CW; Mirsaliotis A; Brighty DW
J Immunol; 2011 Jul; 187(1):361-71. PubMed ID: 21646298
[TBL] [Abstract][Full Text] [Related]
11. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.
Lairmore MD; DiGeorge AM; Conrad SF; Trevino AV; Lal RB; Kaumaya PT
J Virol; 1995 Oct; 69(10):6077-89. PubMed ID: 7545241
[TBL] [Abstract][Full Text] [Related]
12. Expression of HTLV-I envelope protein fused to hydrophobic amino-terminal peptide of baculovirus polyhedrin in insect cells and its application for serological assays.
Nyunoya H; Ogura T; Kikuchi M; Iwamoto H; Yamashita K; Maekawa M; Takebe Y; Miyamura K; Yamazaki S; Shimotohno K
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1311-21. PubMed ID: 2078412
[TBL] [Abstract][Full Text] [Related]
13. Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide.
Frangione-Beebe M; Albrecht B; Dakappagari N; Rose RT; Brooks CL; Schwendeman SP; Lairmore MD; Kaumaya PT
Vaccine; 2000 Dec; 19(9-10):1068-81. PubMed ID: 11137241
[TBL] [Abstract][Full Text] [Related]
14. Antibody reactivity to different regions of human T-cell leukemia virus type 1 gp61 in infected people.
Chen YM; Lee TH; Samuel KP; Okayama A; Tachibana N; Miyoshi I; Papas TS; Essex M
J Virol; 1989 Nov; 63(11):4952-7. PubMed ID: 2677406
[TBL] [Abstract][Full Text] [Related]
15. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
[TBL] [Abstract][Full Text] [Related]
16. Generation and characterization of monoclonal antibodies against multiple epitopes on the C-terminal half of envelope gp46 of human T-cell leukemia virus type-I (HTLV-I).
Tanaka Y; Yasumoto M; Nyunoya H; Ogura T; Kikuchi M; Shimotohno K; Shiraki H; Kuroda N; Shida H; Tozawa H
Int J Cancer; 1990 Oct; 46(4):675-81. PubMed ID: 1698731
[TBL] [Abstract][Full Text] [Related]
17. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
[TBL] [Abstract][Full Text] [Related]
18. Conformation-specific antibodies targeting the trimer-of-hairpins motif of the human T-cell leukemia virus type 1 transmembrane glycoprotein recognize the viral envelope but fail to neutralize viral entry.
Mirsaliotis A; Nurkiyanova K; Lamb D; Woof JM; Brighty DW
J Virol; 2007 Jun; 81(11):6019-31. PubMed ID: 17376912
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
[TBL] [Abstract][Full Text] [Related]
20. Soluble recombinant HTLV-1 surface glycoprotein competitively inhibits syncytia formation and viral infection of cells.
Jassal SR; Lairmore MD; Leigh-Brown AJ; Brighty DW
Virus Res; 2001 Oct; 78(1-2):17-34. PubMed ID: 11520577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
